Glucocorticoid-induced osteoporosis: who to treat with what agent? (Q38266799)

1 September 2017

1 reference

title

Glucocorticoid-induced osteoporosis: who to treat with what agent? (English)

1 reference

glucocorticoid-induced osteoporosis

1 September 2017

0 references

1 reference

1

René Rizzoli

1 reference

1 September 2017

Emmanuel Biver

2

1 reference

PubMed ID

25385412

1 September 2017

language of work or name

English

0 references

publication date

11 November 2014

1 reference

Nature Reviews Rheumatology

1 September 2017

1 reference

1 September 2017

11

1 reference

1 September 2017

98-109

1 reference

1 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2014.188

1 September 2017

0 references

cites work

Use of oral corticosteroids in the United Kingdom

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Prevalence of oral glucocorticoid usage in the United States: a general population perspective.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Oral glucocorticoid use is associated with an increased risk of fracture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Does a Fracture at One Site Predict Later Fractures at Other Sites? A British Cohort Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Use of oral corticosteroids and risk of fractures.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Use of inhaled corticosteroids and risk of fractures.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Are inhaled corticosteroids associated with an increased risk of fracture in children?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Acute changes in calcium and bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Fracture risk with intermittent high-dose oral glucocorticoid therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Management of glucocorticoid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Clinical practice. Glucocorticoid-induced bone disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Effects of low-dose prednisone on bone metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Advances in glucocorticoid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Minireview: live and let die: molecular effects of glucocorticoids on bone cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Osteocyte control of osteoclastogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis--a population based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Are glucocorticoids really deleterious to bone health?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

A histomorphometric study of cortical bone of the iliac crest in patients treated with glucocorticoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Population-Based Trends in Osteoporosis Management after New Initiations of Long-Term Systemic Glucocorticoids (1998–2008)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Change of psychological distress and physical disability in patients with rheumatoid arthritis over the last two decades.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

FRAX and the assessment of fracture probability in men and women from the UK

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Guidance for the adjustment of FRAX according to the dose of glucocorticoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Epidemiology of Childhood Fractures in Britain: A Study Using the General Practice Research Database

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Glucorticoids and bone: some general remarks and some special observations in pediatric patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Do bisphosphonates make children's bones better or brittle?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

How to prevent glucocorticoid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Bioavailability and short-term tolerability of alendronate in glucocorticoid-treated children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Bisphosphonate therapy for children and adolescents with secondary osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Clinical question: What is the best approach to managing glucocorticoid-induced osteoporosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Calcium and vitamin D for corticosteroid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Differences in overlapping meta-analyses of vitamin D supplements and falls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Management of glucocorticoid-induced osteoporosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Influence of glucocorticoids on human osteoclast generation and activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Matrix-embedded cells control osteoclast formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Glucocorticoid dose determines osteocyte cell fate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Cathepsin K inhibitors: a novel target for osteoporosis therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Glucocorticoids are not always deleterious for bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.188

Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis

31 March 2020

1 reference

12 December 2020

Trends in prevention of glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2014.188

1 reference

PubMed ID

25385412

Dimensions Publication ID

1 September 2017

0 references

1 reference

PubMed ID

25385412